In English
NIDA

NIDA Notes Articles: Investigaciones sobre los tratamientos

NIDA Notes Category Graphic

Gene Variants Reduce Opioid Risks

junio del 2014

Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.

NIDA Notes Category Graphic

Dr. Joni Rutter Q&A: How Basic Science Is Tackling Addiction

mayo del 2014

One of NIDA’s goals is to try to understand the individual differences that contribute to whether or not someone who takes a drug will become addicted to it. Dr. Rutter’s research focuses on three types of differences: Environmental, developmental, and genetic and epigenetic.

NIDA Notes Category Graphic

Expanded HIV Screening Projected To Decrease Spread of the Virus

abril del 2014

Intensified screening for HIV among injection drug users receiving opioid agonist therapy could prevent more than twice as many new infections as current screening practice. A recent study based on mathematical modeling found that screening every 6 months instead of annually, and adding viral RNA testing to the currently used HIV antibody testing, could improve both effectiveness and cost-effectiveness.

NIDA Notes Category Graphic

Study: Treat Jail Detainees’ Drug Abuse To Lower HIV Transmission

Marzo del 2014

Active drug use before incarceration was associated with decreased engagement in HIV treatment among HIV-infected jail detainees. The severity of drug dependence correlated with worsening measures of engagement in HIV treatment. The study concludes that evidence-based treatment for drug abuse in jails may result in improved HIV treatment outcomes, which in turn could help slow HIV-transmission rates in the United States.

NIDA Notes Category Graphic

Microneedle Milestone: One Week of Transdermal Drug Delivery

Marzo del 2014

Microneedles are an innovative technique for delivering medications through the skin, a route that could particularly benefit patients receiving naltrexone therapy for opioid and alcohol dependence. Researchers have found a way to use the transdermal technique to deliver a single treatment of naltrexone that lasts for 7 days.

NIDA Notes Category Graphic

California Reaped Large Savings by Diverting Drug-Using Offenders Into Treatment

febrero del 2014

California’s Proposition 36, which allows qualified drug offenders to enter substance use treatment rather than go to jail or prison, saved the state close to $100 million in its first year.

NIDA Notes Category Graphic

HIV Infection Accelerates Hepatitis C–Related Liver Fibrosis

enero del 2014

Study patients with HIV­­–hepatitis C coinfection progressed to successive degrees of severity of liver fibrosis 9 years sooner than those infected with HCV alone. Further findings from the study suggest that suppressing HIV with antiretroviral medications may slow HCV-related liver fibrosis.

NIDA Notes Category Graphic

Medications That Treat Opioid Addiction Do Not Impair Liver Health

diciembre del 2013

A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.

NIDA Notes Category Graphic

Naltrexone Implant Outperforms Daily Pill in Russian Trial

noviembre del 2013

More than half of heroin-addicted patients treated with naltrexone via an implanted delivery device maintained abstinence throughout a 6-month clinical trial in Saint Petersburg, Russia. The implant device, which releases a steady dose of naltrexone continuously for 2 months, averted relapse to heroin use three times as effectively as daily oral doses of the medication.

NIDA Notes Category Graphic

Study Parses Comorbidity of Cannabis Use and Social Anxiety

octubre del 2013

People with cannabis use disorder (CUD) are likely also to have social anxiety disorder (SAD), and comorbid SAD is associated with greater severity of cannabis-related problems. These findings highlight the importance of assessing CUD patients for SAD, as that disorder can be both a contributing cause and a consequence of CUD. Treating both disorders may be a key to helping patients recover from each.

Pages

NIDA Notes

Tags

Drug Topics

Drugs of Abuse

Population Groups

Related Topics

Toma el reto nacional sobre el coeficiente intelectual (CI) sobre las drogas